Biotech News

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST)Twist Bioscience Corporation2026-08-04 12:00 ESTCompany update

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units

Twist Bioscience Corporation

Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by...

Recent company news

TWSTTwist Bioscience Corporation2026-08-05 03:45 EST

Stock data

Close: 109.08 USD
Market cap: 4.37B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Related news

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation

Recent company news

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Stock data